Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RNA-induced silencing complex (RISC) and its core Argonaute machinery represent a fundamental post-transcriptional gene regulation system in eukaryotic cells. At the heart of this ribonucleoprotein complex is an Argonaute protein (predominantly AGO2 in humans), which binds a single-stranded small RNA guide (such as an siRNA or miRNA) to target complementary messenger RNA (mRNA) transcripts. Upon sequence-specific Watson-Crick base pairing, the catalytic PIWI domain of Argonaute acts as an endonuclease to cleave the target mRNA, or recruits downstream factors to repress translation and accelerate mRNA decay. This highly conserved pathway has been successfully co-opted for therapeutic purposes through the development of synthetic siRNA drugs, which act as 'software updates' to direct RISC to silence specific disease-causing genes. While highly potent and catalytic in nature, therapeutic applications of this machinery face challenges such as off-target silencing, potential saturation of endogenous RNAi pathways, and delivery limitations outside of the liver.
The RNA-induced silencing complex (RISC) and its core Argonaute (specifically AGO2) machinery are co-opted by therapeutic small interfering RNAs (siRNAs) or microRNAs (miRNAs). The guide strand of the duplex RNA is loaded into Argonaute, which then uses Watson-Crick base pairing to locate complementary target mRNA transcripts. Upon binding, the catalytic PIWI domain of Argonaute cleaves the target mRNA (slicing) or recruits factors that promote translational repression and mRNA decay, thereby silencing the expression of disease-causing genes. Alternatively, small-molecule inhibitors can bind to Argonaute to block its RNA-binding or catalytic activity, preventing RNA interference.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA-induced silencing complex/Argonaute machinery (RISC).